6505--Amiodarone HCL Tablets

Amendment / Modification

• The hour and date for the receipt of offers has been extended.

• The solicitation closing date and time are modified.

• The deadline for submitting offers is extended from April 7, 2026, at 2:30 PM CT to April 13, 2026, at 2:30 PM CT.

• All other terms and conditions of the original solicitation remain unchanged.

Amendment / Modification

This amendment extends the deadline for the receipt of offers for solicitation 36E79726R0014.

• The hour and date for the receipt of offers has been extended.

• The original deadline of March 31, 2026, has been extended to April 7, 2026, at 2:30 PM CT.

• All other terms and conditions of the original solicitation remain unchanged.

Solicitation / RFP / RFQ

This solicitation is for the supply of Amiodarone Hydrochloride (HCL) Tablets in various strengths and quantities. The contract will establish national contract prices for these pharmaceutical products, which will be distributed through the VA and DoD Pharmaceutical Prime Vendor (PPV) Programs. The objective is to ensure product availability and consistency nationwide with volume-based pricing.

• Products: Amiodarone Hydrochloride (HCL) Tablets, 100 MG (30 tablets/bottle) and 200 MG (60 tablets/bottle and 500 tablets/bottle).

• Packaging: Unit of use bottles must have safety caps, a minimum 120cc volume, and specific label dimensions. Bottles of 400 tablets or less require safety caps. All tablets/capsules must be compatible with automated dispensing units.

• National Drug Code (NDC): Offerors must provide a unique 11-digit NDC number for each offered drug.

• Good Manufacturing Practices (cGMP): Manufacturing facilities must have an acceptable cGMP status with the FDA.

• Bar Coding: All products require GS1-128 or HIBCC compliant bar code labeling.

• DSCSA Compliance: Adherence to Drug Supply Chain Security Act requirements is mandatory.

• Contract Type: Firm Fixed Price, Indefinite-Delivery Requirements contract.

• Period of Performance: Base ordering period of one year, with four one-year option periods, for a total potential duration of five years.

• Distribution: Products will be distributed through Government Prime Vendor contract(s) (McKesson, Cencora, Cardinal Health, DMS Pharmaceutical Group).

• Payment: Contractors will receive payments from PPV programs, not directly from the Government.

• Submission: Proposals must be submitted via email in Microsoft Word or PDF format, including a scanned copy of the signed SF-1449. Faxed proposals are not acceptable. Offerors should confirm receipt of submissions.

• Evaluation: Award will be made to the responsible offeror with the lowest price technically acceptable offer. Technical acceptability includes meeting product descriptions, unique NDC numbers, FDA approval, and FDA cGMP compliance. Past performance will also be evaluated.

• Pricing: Offerors must submit prices for the base year and all four option years for all line items. Prices must not exceed two decimal places and must include a 0.5% Cost Recovery Fee.

• Deadline: Offer Due Date is March 31, 2026, at 2:30 PM.

• This acquisition is unrestricted.

• Offerors not manufacturing the items must submit a Letter of Commitment from the manufacturer.

• All other than small business concerns may be required to submit an approved subcontracting plan.

• Attachments A and B list the current Pharmaceutical Prime Vendor contractors.

• Attachment C provides estimated annual usage quantities by agency.

• Attachment D provides a template for Small Business Subcontracting Plans.

Solicitation / RFP / RFQ

This is a pre-solicitation notice for an unrestricted procurement of Amiodarone Hydrochloride (HCL) Tablets for the Department of Veterans Affairs (VA), including Consolidated Mail Order Pharmacies (CMOPs), State Veterans Homes (SVH), Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). The VA intends to award one contract to a responsible offeror capable of providing an uninterrupted supply. The contract will have a one-year base period with four one-year option periods.

• Procurement of Amiodarone HCL Tablets in 100 MG and 200 MG strengths.

• Estimated annual requirements: 54,951 bottles (30 count) of 100 MG, 108,834 bottles (60 count) of 200 MG, and 18,775 bottles (500 count) of 200 MG.

• Offerors must state the exact drug name as it appears on the label and possess a unique NDC number for the product.

• The successful offeror's label with its unique NDC shall be the only label on the product; VA labels must adhere over the contractor's label.

• Unit of use packaging (30 and 60 count bottles) must include a safety cap (deshellable/convertible) and a bottle with a minimum 120cc volume, cylindrical body, 5.75" circumference, and fit a 5.25" x 2" label.

• Contract period: One year base plus four one-year pre-priced option periods.

• Distribution: Through VA's and DoD's respective Pharmaceutical Prime Vendor Programs.

• Solicitation Number: 36E79726R0014.

• Electronic issuance in accordance with FAR Part 12.

• Tentative closing date: April 2, 2026.

• Interested offerors should monitor SAM.gov for amendments.

• All responsible sources may submit an offer.

• Unrestricted procurement.

• NAICS Code: 325412.

• Point of Contact: Deb Fassl, Contract Specialist, Deborah.Fassl@va.gov, 708-856-5894.

• No paper copies of the solicitation will be available.